MX2020013805A - Derivados de piridopirimidinona para uso como inhibidores de axl. - Google Patents

Derivados de piridopirimidinona para uso como inhibidores de axl.

Info

Publication number
MX2020013805A
MX2020013805A MX2020013805A MX2020013805A MX2020013805A MX 2020013805 A MX2020013805 A MX 2020013805A MX 2020013805 A MX2020013805 A MX 2020013805A MX 2020013805 A MX2020013805 A MX 2020013805A MX 2020013805 A MX2020013805 A MX 2020013805A
Authority
MX
Mexico
Prior art keywords
axl
pyridopyrimidinone derivatives
pyridopyrimidinone
derivatives
axl inhibitors
Prior art date
Application number
MX2020013805A
Other languages
English (en)
Inventor
Hee Kyu Lee
Jung - Ho KIM
Jang - Sik Choi
Dong - Sik Jung
Sung - Ho PARK
Yung - Geun CHOI
Original Assignee
Oscotec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oscotec Inc filed Critical Oscotec Inc
Publication of MX2020013805A publication Critical patent/MX2020013805A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulgan derivados de piridopirimidinona y composiciones farmacéuticas que comprenden los mismos para el uso como un inhibidor de Axl para el tratamiento de un padecimiento o condición mediada por Axl, tales como múltiples tipos de cáncer y metástasis. También se divulgan métodos para tratar un padecimiento o condición mediada por Axl administrando a un sujeto una cantidad terapéuticamente efectiva de los derivados de piridopirimidinona.
MX2020013805A 2018-06-27 2019-06-26 Derivados de piridopirimidinona para uso como inhibidores de axl. MX2020013805A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690620P 2018-06-27 2018-06-27
PCT/KR2019/007733 WO2020004938A1 (en) 2018-06-27 2019-06-26 Pyridopyrimidinone derivatives for use as axl inhibitors

Publications (1)

Publication Number Publication Date
MX2020013805A true MX2020013805A (es) 2021-03-09

Family

ID=68987456

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013805A MX2020013805A (es) 2018-06-27 2019-06-26 Derivados de piridopirimidinona para uso como inhibidores de axl.

Country Status (15)

Country Link
US (1) US20210275532A1 (es)
EP (1) EP3814350A4 (es)
JP (1) JP7200453B2 (es)
KR (1) KR102698500B1 (es)
CN (1) CN112351985B (es)
AU (1) AU2019292207B2 (es)
BR (1) BR112020026641A2 (es)
CA (1) CA3103160C (es)
CL (1) CL2020003340A1 (es)
EA (1) EA202190125A1 (es)
IL (1) IL279593A (es)
MX (1) MX2020013805A (es)
SG (1) SG11202013029UA (es)
WO (1) WO2020004938A1 (es)
ZA (1) ZA202100140B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210024586A (ko) 2018-06-27 2021-03-05 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ES2658290T3 (es) 2009-10-29 2018-03-09 Genosco Inhibidores de cinasa
EP2828259B1 (en) 2012-03-22 2018-08-08 Oscotec, Inc. Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
CA2884921A1 (en) * 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
WO2017059280A1 (en) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
US11191771B2 (en) * 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors

Also Published As

Publication number Publication date
KR102698500B1 (ko) 2024-08-26
SG11202013029UA (en) 2021-01-28
IL279593A (en) 2021-03-01
US20210275532A1 (en) 2021-09-09
CA3103160C (en) 2023-03-07
CL2020003340A1 (es) 2021-04-23
JP7200453B2 (ja) 2023-01-10
EA202190125A1 (ru) 2021-05-24
JP2021528383A (ja) 2021-10-21
EP3814350A4 (en) 2022-05-04
CN112351985B (zh) 2023-12-15
CA3103160A1 (en) 2020-01-02
KR20210014212A (ko) 2021-02-08
WO2020004938A1 (en) 2020-01-02
EP3814350A1 (en) 2021-05-05
AU2019292207A1 (en) 2021-02-18
BR112020026641A2 (pt) 2021-03-30
CN112351985A (zh) 2021-02-09
ZA202100140B (en) 2022-07-27
AU2019292207B2 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
EP4257591A3 (en) Inhibitors of lysine specific demethylase-1
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2020011542A (es) Inhibidores de cd73.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
PH12016502352A1 (en) Pharmaceutical composition
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2022005256A (es) Inhibidores de cd73.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
ZA201901367B (en) Inhibition of olig2 activity
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.